News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial


5/7/2013 11:01:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES